Genenta Science S.p.A. (GNTA)

Biological Products, (No Diagnostic Substances) · market cap $33M · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Genenta Science S.p.A. (GNTA) is an Italian clinical-stage biotech with 13 employees and a $39M market cap trading at approximately $1.44/share. Its pipeline centers on two Phase 2 assets: Pembrolizumab in Clear Cell Renal Cell Carcinoma and Temferon in Glioblastoma Multiforme. A Phase 2 readout on the Pembrolizumab program is estimated by September 30, 2026.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Temferon	Phase 2	Glioblastoma Multiforme

Price & technical context

3-month

-60.0%

6-month

+4.2%

12-month

-78.0%

52-wk range

$0.58–$6.20

vs 50-day MA

-36.1%

vs 200-day MA

-37.5%

Realized vol

149.5%

Max drawdown

-91.6%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for GNTA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.